Overall survival of first-line axitinib in metastatic renal cell carcinoma: Japanese subgroup analysis from phase II study - Wikidata - wikimedia - TriplyDB

Overall survival of first-line axitinib in metastatic renal cell carcinoma: Japanese subgroup analysis from phase II study

Overall survival of first-line axitinib in metastatic renal cell carcinoma: Japanese subgroup analysis from phase II study

http://www.wikidata.org/entity/Q33823247

about

MicroRNA-590-5p regulates cell viability, apoptosis, migration and invasion of renal cell carcinoma cell lines through targeting ARHGAP24.Pharmacogenetics-based area-under-curve model can predict efficacy and adverse events from axitinib in individual patients with advanced renal cell carcinoma.

P2860

Q47667730-86091FBA-4E0C-4014-BD5D-EBD0B57F6DD5 Q52571238-222C8890-E330-4C81-B2E2-E3F5B976AE86

P2860

Overall survival of first-line axitinib in metastatic renal cell carcinoma: Japanese subgroup analysis from phase II study

http://www.wikidata.org/entity/Q33823247

description

2017 nî lūn-bûn

@nan

2017 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2017 թվականի մարտին հրատարակված գիտական հոդված

@hy

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

name

Overall survival of first-line ...... p analysis from phase II study

@ast

Overall survival of first-line ...... p analysis from phase II study

@en

type

label

Overall survival of first-line ...... p analysis from phase II study

@ast

Overall survival of first-line ...... p analysis from phase II study

@en

prefLabel

Overall survival of first-line ...... p analysis from phase II study

@ast

Overall survival of first-line ...... p analysis from phase II study

@en

P1433

Q33823247-D2131BD7-C56D-4DE0-9FF2-9CD4F23F2B90

P1476

Q33823247-34A353AD-1EB4-4B18-95F5-5E86670F746A

P2093

Q33823247-19B54140-DF29-4DA7-BEB9-09455D1C2132

Q33823247-19FB7953-3EF3-413D-B4B3-9473BB78CB1A

Q33823247-38658A15-802F-4A17-856E-4B7C6F59560C

Q33823247-6E04FCE1-661F-4A9C-AE91-14241F138A4D

Q33823247-6F3BBF5E-9B0F-441C-BA77-3297D67C892F

Q33823247-93E08707-0E8D-4457-95F6-F03F8A270F3D

Q33823247-982489D4-4778-437B-9853-9C373B4A821A

Q33823247-B4B0F6E1-5426-422C-8C70-C016A61B3E27

Q33823247-D9BB7D66-C799-44BF-BEB5-460C54A1C933

Q33823247-EE865B9F-8963-4E16-996B-A3C49B0BB51F

P2860

Q33823247-02230CBB-ADE3-43F0-A123-38D0FE01BC85

Q33823247-0432BC59-CB34-4348-A088-B29AC25D2838

Q33823247-087707DA-C833-466A-A2DB-94AA241CCCF9

Q33823247-0DF9DAEC-C828-4466-9D9C-77521A528B52

Q33823247-3D327FF5-5271-4444-9A50-7F3999DED17A

Q33823247-42BDB77C-3F84-4AFF-9868-8F1518A4BD62

Q33823247-50B0888B-222E-43E7-A2EF-B61D3C26C1AD

Q33823247-5CEEA0D1-74D1-43DA-ADF8-D7CC6357F705

Q33823247-65E6D9A1-E49A-406D-866A-D8FCBCFEB8F7

Q33823247-6B54061C-D643-4844-8308-38E3427EA549

P304

Q33823247-DC4021A0-E107-487C-9F80-1BA501E72BB3

P31

Q33823247-608224A1-EFDA-4F35-8F19-E261A37128BD

P356

Q33823247-1197E076-28A3-45B4-B11F-A20AF2971A58

P433

Q33823247-1B3C6CD8-01A6-489F-A6C5-3B5C1F8168A1

P478

Q33823247-D56021DA-B457-4F55-A4EE-5028EFD6C75B

P50

Q33823247-E5C332DF-826B-4AB0-908F-C82487D282F6

P577

Q33823247-A3FCECDD-D294-4559-BE51-E8870F57344D

P698

Q33823247-2573B1EC-6967-49A7-82A2-2C3045CEFB2C

P932

Q33823247-D0D1F6F9-6DF7-4C07-9791-9AD84F2833CF

P356

P1433

P1476

Overall survival of first-line ...... p analysis from phase II study

@en

P2093

Angel H Bair

http://www.w3.org/2001/XMLSchema#string

Brian I Rini

http://www.w3.org/2001/XMLSchema#string

Hirotsugu Uemura

http://www.w3.org/2001/XMLSchema#string

Nobuo Shinohara

http://www.w3.org/2001/XMLSchema#string

Satoshi Fukasawa

http://www.w3.org/2001/XMLSchema#string

Tomonori Habuchi

http://www.w3.org/2001/XMLSchema#string

Yoichi Kamei

http://www.w3.org/2001/XMLSchema#string

Yoshihiko Tomita

http://www.w3.org/2001/XMLSchema#string

Yoshiko Umeyama

http://www.w3.org/2001/XMLSchema#string

Yosuke Fujii

http://www.w3.org/2001/XMLSchema#string

P2860

Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study.

Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial

Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.

Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial.

Overall survival and final efficacy and safety results from a Japanese phase II study of axitinib in cytokine-refractory metastatic renal cell carcinoma

Prognostic outcome in patients treated with tyrosine kinase inhibitors as first-line molecular-targeted therapy for metastatic renal cell carcinoma: Experience in real-world clinical practice in Japan.

Phase II clinical trial of sorafenib plus interferon-alpha treatment for patients with metastatic renal cell carcinoma in Japan.

Efficacy and safety of axitinib versus sorafenib in metastatic renal cell carcinoma: subgroup analysis of Japanese patients from the global randomized Phase 3 AXIS trial.

Key predictive factors for efficacy of axitinib in first-line metastatic renal cell carcinoma: subgroup analysis in Japanese patients from a randomized, double-blind phase II study.

Key predictive factors of axitinib (AG-013736)-induced proteinuria and efficacy: a phase II study in Japanese patients with cytokine-refractory metastatic renal cell Carcinoma.

P304

1231-1239

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/CAS.13232

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

108

http://www.w3.org/2001/XMLSchema#string

P50

P577

2017-05-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28267243

http://www.w3.org/2001/XMLSchema#string

P932

5480076

http://www.w3.org/2001/XMLSchema#string